tiprankstipranks
Advertisement
Advertisement

BIOA Stock Latest News

AMD, Under Armour downgraded: Wall Street’s top analyst calls
The FlyAMD, Under Armour downgraded: Wall Street’s top analyst calls
9d ago
UA
AMD
BioAge Labs initiated with a Buy at BTIG
PremiumThe Fly
BioAge Labs initiated with a Buy at BTIG
10d ago
BIOA
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
PremiumRatings
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data
11d ago
BIOA
BioAge Labs reports Q1 EPS (52c), consensus (63c)
PremiumThe Fly
BioAge Labs reports Q1 EPS (52c), consensus (63c)
14d ago
BIOA
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating
PremiumRatings
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating
1M ago
BIOA
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
PremiumThe FlyBioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
1M ago
BIOA
BioAge Labs initiated with a Buy at Needham
Premium
The Fly
BioAge Labs initiated with a Buy at Needham
2M ago
BIOA
BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating
Premium
Ratings
BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating
2M ago
BIOA
BioAge Labs files automatic mixed securities shelf
PremiumThe Fly
BioAge Labs files automatic mixed securities shelf
2M ago
BIOA
BioAge Highlights BGE-102 Progress and Financial Strength
PremiumCompany Announcements
BioAge Highlights BGE-102 Progress and Financial Strength
2M ago
8K
BIOA
BIOA Earnings this Week: How Will it Perform?
PremiumPre-Earnings
BIOA Earnings this Week: How Will it Perform?
2M ago
BIOA
BioAge Labs price target raised to $52 from $15 at Citi
PremiumThe Fly
BioAge Labs price target raised to $52 from $15 at Citi
2M ago
BIOA
BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal
PremiumRatingsBioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal
3M ago
BIOA
BioAge Labs initiated with an Outperform at Oppenheimer
Premium
The Fly
BioAge Labs initiated with an Outperform at Oppenheimer
3M ago
BIOA
VTYX
Midday Fly By: Berkshire cuts Amazon stake, MSG Sports weighs spinoff
Premium
The Fly
Midday Fly By: Berkshire cuts Amazon stake, MSG Sports weighs spinoff
3M ago
T
CHT
BioAge Labs upgraded to Buy from Hold at Jefferies
PremiumThe Fly
BioAge Labs upgraded to Buy from Hold at Jefferies
3M ago
BIOA
BioAge Labs price target raised to $23 from $12 at Morgan Stanley
PremiumThe Fly
BioAge Labs price target raised to $23 from $12 at Morgan Stanley
4M ago
BIOA
BioAge Labs initiated with an Overweight at Piper Sandler
PremiumThe Fly
BioAge Labs initiated with an Overweight at Piper Sandler
4M ago
BIOA
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating
PremiumRatings
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating
4M ago
BIOA
BioAge Labs Announces Upsized Public Equity Offering
PremiumCompany AnnouncementsBioAge Labs Announces Upsized Public Equity Offering
4M ago
8K
BIOA
Closing Bell Movers: Netflix down 5% after soft guidance
Premium
The Fly
Closing Bell Movers: Netflix down 5% after soft guidance
4M ago
HWC
OZK
BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating
Premium
Ratings
BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating
4M ago
BIOA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >